Enterprise Therapeutics, a biopharmaceutical company developing novel therapies to improve the lives of patients suffering from respiratory disease, has appointed Dr Niyati Prasad as chief medical officer.
With extensive experience in respiratory drug development, Dr Prasad will offer full-time, UK-based support to lead the continued advancement of the Brighton-based company’s clinical programmes.
She was most recently senior director of clinical development at GSK and has also held leadership roles at Galapagos, Vertex, Takeda and Novartis.
Enterprise is developing novel disease-modifying therapies which target the underlying mechanisms of mucus congestion, to enhance the clearance of mucus from the airways, restore lung function and ultimately to reduce morbidity and mortality in chronic respiratory diseases like cystic fibrosis.
Its ETD001 inhibitor will be evaluated in a phase 2 clinical trial later this year.
“Niyati’s long-standing expertise in respiratory drug development and impressive track record in directing clinical programmes will be an invaluable asset to Enterprise,” said CEO Dr John Ford.
“We are confident that Dr Prasad will play a key role in progressing our novel respiratory therapies through the clinic.”
Dr Prasad added: “Enterprise is a dynamic and exciting company, with its programmes offering huge potential, especially in the treatment of cystic fibrosis regardless of underlying mutations.
“I look forward to working closely with the team to bring these novel therapies for respiratory disease to patients.”